Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Transformed Recurrent Non-Hodgkin Lymphoma

Known as: Transformed Recurrent Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma Transformed Recurrent, Transformed Lymphoma 
The reemergence of non-Hodgkin lymphoma transformed after a period of remission.
National Institutes of Health

Related topics

Related topics

12 relations
Atypical lymphocyteHematopoietic and Lymphoid CellHematopoietic and Lymphoid TissueLymphatic System
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL.
Ibrutinib has generated remarkable responses in patients with chronic lymphocytic leukemia (CLL), including those with an… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 2
  • figure 4
2014
2014
Continuum-Discretized Coupled-Channels calculations with core excitation
The effect of core excitation in the elastic scattering and breakup of a two-body halo nucleus on a stable target nucleus is… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
2014
2014
Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy
The optimum follow-up of patients with transformed indolent lymphoma (TrIL) is not well defined. We sought to determine the… Expand
  • table 1
  • table 2
  • table 2
Highly Cited
2013
Highly Cited
2013
Multifunctional NH2-mediated zirconium metal-organic framework as an efficient visible-light-driven photocatalyst for selective oxidation of alcohols and reduction of aqueous Cr(VI).
Metal-organic frameworks (MOFs) have been arousing a great interest owing to their unique physicochemical properties. In this… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Highly Cited
2011
Highly Cited
2011
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
BACKGROUND Lenalidomide is an immunomodulatory agent with antitumor activity in B-cell malignancies. This phase II trial aimed to… Expand
2011
2011
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non‐Hodgkin lymphoma of distinct histological origin
Transformed lymphoma (TL) represents a heterogeneous group of lymphomas with an aggressive course and poor prognosis. We assessed… Expand
Highly Cited
2009
Highly Cited
2009
The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL).
BACKGROUND We previously correlated non-Hodgkin's lymphoma (NHL) histology with (18)fluoro-2-deoxyglucose-positron emission… Expand
Review
2002
Review
2002
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue
  • F. Hagemeister
  • Cancer Chemotherapy and Pharmacology
  • 2002
    • Corpus ID: 25774613
Abstract. Treatment of aggressive lymphoma in relapse is difficult. Patients who initially present with these diseases often know… Expand
2001
2001
Molecular mechanisms of transcriptional control of bcl-2 and c-myc in follicular and transformed lymphoma.
A synergistic interaction of Bcl-2 and c-Myc plays a role in lymphomagenesis in mice and in some patients as well. Progression of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 6
1980
1980
Selection for virulence and organ‐specific metastasis of herpesvirus‐transformed lymphoma cells
The Marek's Disease virus‐transformed, non‐producer, lymphoma cell line, MDCC‐RP1, was selected by sequential transplantation to… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE